Treosulfan in the treatment of advanced ovarian cancer: A randomised co-operative multicentre phase III-study

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2923-2932

  Breitbach, G P ^a   Meden, H ^b,g   Schmid, H ^f   Kuhn W ^c   Sass, G ^d   Schach, S ^h   Schmidt Rohde, P ^e   Bastert, G ^f  

^a Clinic for Internal Medicine Community Hospital Neunkirchen gGmbH   (Germany)

^b Department of Nuclear Medicine   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MEDAC GMBH   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g Chefarzt der Frauenklinik   (Germany)

^h NONE

Author keywords

Chemotherapy; Cisplatin; Cyclophosphamide; Ovarian cancer; Treosulfan

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; TREOSULFAN;

ADVANCED CANCER; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; REMISSION INDUCTION;

EID: 0036765926     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ziegler H, Stegmaier C: Bevölkerungsbezogene Krebsregistrierung in Deutschland. Onkologie 19: 268-277, 1996.
2. Bertelsen K: Tumour reduction surgery and long-term survival in advanced ovarian cancer: a DACOV-study. Gynecol Oncol 38: 203-9, 1990.
3. Williams CJ, Mead GM and Macbeth FR: Cisplatin combination therapies versus chlorambucil in advanced ovarian carcinoma: mature results of a randomised trial. J Clin Oncol 3: 1455-62, 1985.
4. Neijt JP, ten Bokkel Huinink WW and van der Burg ME: Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma. Lancet 2: 594-600, 1984.
5. Ozols RF: Ovarian cancer, part II: Treatment. Curr Probl Cancer 16: 63-126, 1992.
6. Breitbach GP: In G. Bastert (Ed.): Neue Aspekte in der Therapie hormonrefraktärer Tumore, Aktuelle Onkologie 72, W. Xuckschwerdt Verlag, München, Bern, Wien, New York, p. 1-10, 1993.
7. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation, 1979.
8. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-81, 1958.
9. Agresti A: Categorical Data Analysis. New York: John Wiley, 1990.
10. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34: 187-220, 1972.
11. Ulrich J: Die Lebensqualität von Ovarialkarzinompatientinnen unter Chemotherapie. Dissertation Philipps-University of Marburg, 1993.
12. McGuire WP, Hoskins WJ, Brady MF and Kucera PR: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. NEJM 334: 1-6, 1996.
13. Muggia FM, Braly PS, Braly MF, Sutton G, Copeland LJ, Lentz SL, Alvarez RD, Kucera PR and Small J: Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study # 132. Proc Am Soc Onc 16: 352a (Abstract 1257), 1997.
14. Poole C, Perren TJ, Jordan SD, Jenkins AH, Herod JJO, Burton A, Mould JJ, Spooner DA, Luesly D and Earl HM: Sequential paclitaxel and cisplatin chemotherapy in patients with newly diagnosed epithelial ovarian cancer. Proc Am Soc Onc 16: 356a (Abstract 1271), 1997.
15. Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy JA and Piccart MJ: Updated analyis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc Am Soc Onc 17: 361a (Abstract 1394), 1998.
16. du Bois A, Richter B, Warm M, Costa S, Bauknecht T, Lück HJ, Meier M and Möbus V: Cispatin/paclitaxel vs. carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proc Am Soc Onc 17: 361a (Abstract 1395), 1998.